Loading...
•
Sep 30, 2022
Ocugen Q3 2022 Earnings Report
Ocugen reported financial results and provided a business update for Q3 2022.
Key Takeaways
Ocugen reported a net loss of $0.10 per share for the third quarter ended September 30, 2022. The company's cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022. They believe that their current cash and cash equivalents balance will enable them to fund its operations into Q4 2023.
Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trial
Expanded product pipeline with OCU500—Ocugen’s mucosal COVID-19 vaccine and OCU410ST for Stargardt disease
Completed enrollment of U.S. Phase 2/3 COVAXIN™ (BBV152) clinical trial
Top line data for COVAXIN™ is expected in early 2023.
Forward Guidance
Ocugen anticipates achieving multiple milestones across its programs next year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...